Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 18/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962368 | 0.79 | — | — | |
| SCHEMBL24924285 | 0.76 | — | — | |
| SCHEMBL469204 | 0.74 | SLC6A3 (0.38) | SLC6A3SLC6A2DRD4ACACBSLC6A4 | |
| SCHEMBL1911589 | 0.71 | SLC6A3 (0.38) | SLC6A3SLC6A2 | |
| SCHEMBL13995170 | 0.70 | SCN10A (0.36) | SLC6A3SLC6A2 | |
| SCHEMBL20470431 | 0.69 | CTSK (0.42) | SLC6A3SLC6A2DRD4ACACBSLC6A4 | |
| SCHEMBL9480 | 0.69 | PARP15 (0.43) | SLC6A3SLC6A2ACACB | |
| SCHEMBL12134656 | 0.68 | PDE10A (0.36) | SLC6A3SLC6A2 | |
| SCHEMBL105278 | 0.68 | SLC6A3 (0.39) | SLC6A3SLC6A2DRD4 | |
| SCHEMBL13412533 | 0.68 | SLC6A3 (0.36) | SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9238647-B2 | P2X3 receptor antagonists for treatment of pain | MERCK SHARP & DOHME CORP. (US) | 2016-01-19 | — | — | US | disclosed |
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | MERCK SHARP & DOHME LLC | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064181-A1 | P2X3 Receptor Antagonists for Treatment of Pain | P2RX3, P2RX1, P2RX2 | SLC6A3 553/4885SLC6A2 942/4885DRD4 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.